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Background. Metabolic alterations as hyperglycemia and inﬂammation induce myocardial molecular events enhancing oxidative
stress and mitochondrial dysfunction. Those alterations are responsible for a progressive loss of cardiomyocytes, cardiac stem
cells, and consequent cardiovascular complications. Currently, there are no eﬀective pharmacological measures to protect the
heart from these metabolic modiﬁcations, and the development of new therapeutic approaches, focused on improvement of the
oxidative stress condition, is pivotal. The protective eﬀects of levocarnitine (LC) in patients with ischemic heart disease are
related to the attenuation of oxidative stress, but LC mechanisms have yet to be fully understood. Objective. The aim of this
work was to investigate LC’s role in oxidative stress condition, on ROS production and mitochondrial detoxifying function in
H9c2 rat cardiomyocytes during hyperglycemia. Methods. H9c2 cells in the hyperglycemic state (25mmol/L glucose) were
exposed to 0.5 or 5mM LC for 48 and 72 h: LC eﬀects on signaling pathways involved in oxidative stress condition were studied
by Western blot and immunoﬂuorescence analysis. To evaluate ROS production, H9c2 cells were exposed to H2O2 after LC
pretreatment. Results. Our in vitro study indicates how LC supplementation might protect cardiomyocytes from oxidative stress-
related damage, preventing ROS formation and activating antioxidant signaling pathways in hyperglycemic conditions. In
particular, LC promotes STAT3 activation and signiﬁcantly increases the expression of antioxidant protein SOD2.
Hyperglycemic cardiac cells are characterized by impairment in mitochondrial dysfunction and the CaMKII signal: LC
promotes CaMKII expression and activation and enhancement of AMPK protein synthesis. Our results suggest that LC might
ameliorate metabolic aspects of hyperglycemic cardiac cells. Finally, LC doses herein used did not modify H9c2 growth rate and
viability. Conclusions. Our novel study demonstrates that LC improves the microenvironment damaged by oxidative stress
(induced by hyperglycemia), thus proposing this nutraceutical compound as an adjuvant in diabetic cardiac regenerative medicine.
1. Introduction
Cardiovascular complications are recognized as the primary
cause of mortality in subjects with diabetes mellitus (DM)
[1, 2], characterized by hyperglycemia which is determined
by a defect of insulin secretion, insulin action, or both [3].
Moreover, DM is associated with inﬂammation condition.
Chronic hyperglycemia, characterizing overt diabetes, or
ﬂuctuant hyperglycemia, present in the prediabetic condi-
tion, are responsible for the activation of numerous signaling
pathways that exacerbate the systemic inﬂammation and lead
to the development of diabetic complications [4, 5]. Recent
evidence establishes how hyperglycemia is involved in the
regulation of sirtuin (SIRT) transcription factors. The dereg-
ulation of SIRT expression is strictly correlated with the pro-
gression of inﬂammation and atherosclerotic disease. In
particular, Balestrieri et al. demonstrated that SIRT6 protein
expression is downregulated in atherosclerotic plaques of
diabetics, and this defect is linked to the chronic oxidative
stress condition [6]. Those evidences indicate that chronic
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inﬂammation, oxidative stress condition and predisposition
to ischemic heart disease are higher in patients with DM than
in nondiabetics [7, 8].
Traditional therapeutic approaches as well as innovative
promising strategies [7] (i.e., stem/progenitor cell therapy,
existing cardiomyocyte proliferation, and reprogramming
noncardiac cells) are limited in patients withDM[8–11]. Peri-
procedural intensiveglycemiccontrol, duringearlypercutane-
ous coronary intervention in diabetic patients, was shown to
improve myocardial protection by increasing SIRT1 expres-
sion, endothelial progenitor cell number, and their capability
to diﬀerentiate in mature cardiomyocytes [12]. Hyperglyce-
mia in diabetic subjects is the major factor responsible for the
failure of regenerative myocardial therapeutic strategies.
Recent data indicate that the overproduction of reactive oxy-
gen species (ROS) and the oxidative stress condition are the
main causes involved in diabetic cardiac injury and in the lack
of success in cardiac regenerative therapies [13–17].Hypergly-
cemia enhances ROS production impairing cardiac microen-
vironment and regeneration capacity [16, 17]. In particular,
several publications showed that the hyperglycemic and oxi-
dative microenvironment induces mitochondrial abnormali-
ties and cellular damage, eventually leading to senescence
and apoptosis of cardiac progenitors [18, 19].
Thus, to optimize regenerative strategies for diabetic
patients, the development of new therapeutic approaches
focused on the reduction of oxidative stress condition is
fundamental.
Noteworthy, in recent years, L-carnitine (LC) has been
proposed as a nutraceutical integrator in the treatment of
numerous cardiac syndromes, including coronary disease,
atherosclerosis, and toxic myocardial injury [20–22]. It is
well established that LC, facilitating transport of long-chain
fatty acids into the mitochondrial matrix, plays an important
role in supporting cardiac energy homeostasis [23–25]. Most
importantly, some studies successfully showed LC’s ability to
reduce oxidative stress, hypoxic cellular damage, and apo-
ptosis of cardiac cells in normal glycemic condition [26, 27].
In particular, Mao et al. have recently demonstrated that
LC pretreatment ameliorated cellular damage induced by
H2O2 in H9c2 rat cardiomyocytes, enhancing mitochon-
drial function [28].
LC eﬀects on cardiac metabolism and function have been
demonstrated under a variety of clinical conditions [29, 30],
while LC antioxidative eﬀects in hyperglycemic cardiomyo-
cites were not investigated, yet.
The aim of this study is to investigate in vitro LC ability to
counteract oxidative stress condition, modifying ROS pro-
duction and promoting mitochondrial detoxifying function
in H9c2 rat cardiomyocytes under hyperglycemic condition
(25mmol/L glucose). The goal is to identify in LC a novel
adjuvant agent in cell therapy able to ameliorate the microen-
vironment of the hyperglycemic heart, thereby supporting
cardiac progenitor cell proliferation and diﬀerentiation.
2. Materials and Methods
2.1. Chemicals and Reagents. All utilized reagents were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Primary antibodies against GAPDH (FL-335), p-CaMKII
α (22B1), CaMKII (M-176), AMPK α1/2 (H-300), SOD2
(FL-222), p21 (C-19), peroxidase-conjugated secondary
antibodies for Western blot analysis, and FITC-conjugated
antibodies for immunoﬂuorescence study were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
STAT3 (124H6) and p-STAT3 (Ser727) were purchased
from Cell Signaling Technology (Danvers, MA, USA).
The CellROX® Oxidative Stress Reagent kit (C10443)
was purchased from Thermo Fisher Scientiﬁc, Life Technol-
ogies Italia (Monza, Italy).
2.2. Cell Line and Culture Conditions. The American Type
Culture Collection (ATCC, Manassas, VA, USA) oﬀered
the cardiomyoblast H9c2 cell line of rat embryo. The H9c2
cell line was regularly cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM, Gibco, Grand Island, NY, USA) contain-
ing 25mmol/L glucose, 100μg/mL streptomycin (Sigma-
Aldrich, St. Louis, MO, USA), 100U/mL penicillin, and
10% fetal bovine serum (FBS, Gibco, Grand Island, NY,
USA) in 75 cm2 tissue culture ﬂasks and then incubated at
37°C by adopting 5% CO2. H9c2 cells exposed to high glucose
(25mmol/L) represent a validated in vitro model in order to
mimic cardiac hyperglycemic/diabetic condition [31, 32].
Cells were fed every day; following literature indications,
H9c2 cells were split when reaching 70–80% conﬂuence in
order to prevent the loss of the diﬀerentiation potential [28,
32]. Preliminarily, we evaluated the eﬀective concentration
of LC based on our previous work performed on skeletal
myoblasts and literature evidence (data not shown) [28,
33]. We identiﬁed the correct LC concentrations as the lower
concentrations that activated STAT3 signaling. Then, H9c2
cells in the active proliferation phase were treated with 0.5
or 5mM LC as indicated in Figure 1.
2.3. Growth Curve and Cell Viability Test. H9c2 cells were
plated on 60mm× 15mm culture dishes at 20% conﬂuence
and grown in DMEM. After an overnight phase, the cells
were treated or not with 0.5 or 5mM LC. At 24, 48, and
72 h after treatments, cells were trypsinized and stained with
trypan blue and were counted using hemocytometer. The
average values for each single day were used to plot a
growth curve. Cell viability was calculated by dividing the
unstained viable cell count by the total cell count. In addi-
tion, morphological changes were observed daily by phase
contrast microscopy.
LC 5 mM
LC 0.5 mM
CONTR
48 h 72 h
T0 = 40%
confluence
Figure 1: Scheme of treatment. Upon reaching 40% conﬂuence,
H9c2 cells were treated for 48 and 72 h with 0.5 or 5mM LC.
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2.4. Western Blot Analysis. Western blot analysis was per-
formed as described previously [34]. Cell lysates were pre-
pared using RIPA buﬀer implemented with protease
inhibitors. 30μg of proteins was separated by SDS-
polyacrylamide gel electrophoreses (SDS-PAGE) and elec-
trophoretically transferred to nitrocellulose membranes
(Protran®, Whatman® Schleicher & Schuell). The blots
were then blocked and incubated with speciﬁc primary
antibodies, followed by incubation with anti-species-
speciﬁc secondary antibodies. To conﬁrm equal protein
loading per sample, we used GAPDH protein as house-
keeping protein. Finally, detection of speciﬁc proteins
was performed by enhanced chemoluminescence reagent
(Western Lightning ECL Pro, Perkin Elmer). Quantitative
measurement of immunoreactive band intensities was per-
formed by densitometric analysis using the Scion Image
software (Scion Corporation, Frederick, MD, USA). Data
were then converted into fold changes (FC) of the control.
2.5. Immunoﬂuorescence Studies. H9c2 cells were grown on
coverslips with or without LC 0.5 or 5mM LC. After 48
and 72 h of treatment, cells were washed 3 times with
PBS, then ﬁxed in prepared 4% paraformaldehyde for 20
minutes. The cells on the coverslips were washed with
PBS and incubated for 30minutes at room temperature
with 1% bovine serum albumin in PBS with 0.2% Triton
X-100. At that point, H9c2 cells were incubated with pri-
mary antibodies for 120 minutes. To detect the primary
antibody, binding site cells were washed three times in
PBS and followed by incubation with speciﬁc antibodies
FITC-conjugated for 90 minutes. Nuclei were revealed
with DAPI staining. Coverslips with cells were mounted
and observed using Nikon Eclipse 50I microscopy. The
images were captured using Nis-Elements D 4.00 software.
Immunoﬂuorescence signals were estimated using the Ima-
geJ program (http://imagej.nih.gov/ij/). Data were displayed
and analyzed using Adobe Photoshop CS4®.
Automated quantiﬁcation on the immunoﬂuorescence
signal was performed by using the ImageJ program
(http://imagej.nih.gov/ij/) [34]. For each analyzed protein,
the quantiﬁed signal was normalized for the total nuclei
number.
2.6. Intracellular ROS Determination in H9c2 Cells after H2O2
Injury. Intracellular ROS levels were valued using the Cell-
ROX® Oxidative Stress Reagent kit. Brieﬂy, H9c2 cells were
pretreated with 0.5 or 5mM LC for 48 h, and then they were
exposed to 500μM H2O2 for 30min. At the end of the H202
injury, the ﬂuorogenic probe of the kit was added
(Figure 2(a)). CellROX® Oxidative Stress Reagents are
ﬂuorogenic probes designed to reliably measure ROS in live
cells. The cell-permeable reagents are nonﬂuorescent or very
faintly ﬂuorescent while in a reduced state and during oxida-
tion exhibit a strong ﬂuorogenic signal. The CellROX®
Orange Reagent signal is localized in the cytoplasm.
The images were captured using Nis-Elements D 4.00
software. Data were displayed and analyzed using Adobe
Photoshop CS4®.
Automated quantiﬁcation on the immunoﬂuorescence
signal was performed by using the ImageJ program
(http://imagej.nih.gov/ij/) [35]. For each analyzed pro-
tein, the quantiﬁed signal was normalized for the total
nuclei number.
2.7. Statistical Analysis. All experiments were performed
three times. The data are expressed as the means± standard
deviation, and statistical comparisons were performed with
speciﬁc statistical packages (Prism v 7.00 GraphPad Soft-
ware, San Diego, CA, USA). Diﬀerences were analyzed by
one- or two-way analysis of variance (ANOVA) followed
by Tukey’s multiple comparison post hoc test. p < 0 05 was
considered statistically signiﬁcant.
3. Results
3.1. Attenuation of ROS Production Induced by H2O2 in LC
Pretreated H9c2 Cells. The diabetic heart usually has ROS
levels that exceed normal quantities, and ROS overproduc-
tion likely contributes to cardiomyopathy [15, 36, 37]. After
stimulus with 500μM H2O2, 48 h pretreatment with 0.5 or
5mM LC markedly reduced ROS levels with respect to the
CONTR condition (Figures 2(b) and 2(c)). Furthermore,
DAPI images showed that pretreated H9c2 cells with LC, in
particular with 5mM LC, showed a higher number of nuclei
than the control condition (Figures 2(b) and 2(d)): These
results suggested that LC pretreatment improved cellular sur-
vival after H2O2 injury.
3.2. LC Improves Antioxidant Response in H9c2 Cells under
Hyperglycemic Condition. Signal transducer and activator of
transcription 3 (STAT3) activation thought phosphorylation
on Ser727 is an important protective mechanism to prevent
ROS generation in the setting of oxidative stress [38–40].
Under normoxic conditions, the treatment with 0.5 or
5mM LC for 48 and 72 h signiﬁcantly enhanced myocardial
STAT3 phosphorylation on Ser727 (Figure 3(a)).
Moreover, after 48 and 72 h of treatment, exposure of
cells to 0.5mM LC caused rapid increase of SOD2, a well-
known antioxidant enzyme [41]. This eﬀect was signiﬁcantly
augmented with the 5mM LC dose (Figure 3(b)).
3.3. LC Downregulation of CaMKII Pathway. Ca2+/calmodu-
lin-dependent protein kinase II (CaMKII), a multifunctional
serine/threonine protein kinase, is implicated in the path-
ogenesis of cardiac diseases [42, 43] promoting ROS over-
production [44, 45]. As shown by immunoﬂuorescence
analysis (Figure 4(a)), compared with untreated H9c2
cells, LC treatments decreased CaMKII and pCaMKII-
positive cell numbers after 72 h of stimuli: immunoﬂuores-
cence quantiﬁcation shows a greater eﬀect with the 5mM
LC dose. Furthermore, after 72 h, either 0.5 or 5mM doses
of LC signiﬁcantly decreased the phosphorylation of
CaMKII α isoform, as shown by Western blot analysis
(Figure 4(b)).
3.4. LC Action on AMPK Protein Expression. 5′-AMP-
activated kinase (AMPK) has become a strategic cellular
target for the cure of cardiovascular disease correlated
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with DM [46–48]: it is likely that AMPK activity in the
diabetic heart may ameliorate cardiac function. After LC
stimuli, immunoﬂuorescence for AMPK showed an increase
in AMPK-positive cells in a dose- and time-dependent
manner (Figure 5).
3.5. LC Action on Cardiomyocyte Viability. An uncon-
trolled consequence of sustained hyperglycemia is the
induction of cardiomyocyte death that causes a loss of
contractile units, which declines organ function and pro-
vokes hypertrophy of vital cardiomyocytes [49–51]. We
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Figure 2: Attenuation of ROS production induced by H2O2 in LC-pretreated H9c2 cells. (a) Scheme of treatment: H9c2 cardiomyocytes were
exposed to a stressful insult with 500 μM of H2O2 after pretreatment for 48 h with 0.5 or 5mM LC. (b) Using the CellROX reagent assay, LC
action was evaluated under oxidative stress conditions. The pretreatment with 0.5 or 5mM LC causes a reduction in ROS production after
stimulus with 500 μM of H2O2. (c) Quantiﬁcation of ROS production. The quantiﬁed signal was normalized for the total nuclei number.
From the DAPI images, it was possible to observe that the cells pretreated with both doses of LC show higher survival compared to the
control cells. (d) Quantiﬁcation of nuclei number pre- and after H2O2 injury in LC-pretreated H9c2 cells. Data are expressed as fold
changes (FC) of mean± SD. Signiﬁcance: ∗∗p ≤ 0 01 vs. CONTR.
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investigated viability and morphologic features of H9c2
cells after exposure to 0.5 or 5mM LC (Figure 6(a)).
The growth curve showed that LC treatments did not induce
a change of cellular proliferation with respect to untreated
control cells (Figure 6(b)). Moreover, the viability graph
showed the absence of cell mortality in all treatment condi-
tions (Figure 6(b)). To support these data, phase contrast
images, collected at day 3 of the growth curve, conﬁrmed
the absence of morphological changes in cells treated with
0.5 or 5mM LC respect to control (Figure 6(c)).
In opposition to its antiproliferative functions, p21 can
also play proproliferative and survival roles when it is local-
ized in the cytosol [51]. Figure 6(c) shows that the protein con-
tent of p21 in cardiomyocytes treated with 0.5 or 5mM LC
was superimposable to control cells, and this result highlights
that there is not p21 translocation from cytoplasm to nuclei.
LC 0.5 mM
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(b)
Figure 3: LC improves antioxidant response in H9c2 cells under hyperglycemic condition. (a) Representative Western blot and relevant
quantiﬁcation: LC stimuli for 48 and 72 h signiﬁcantly enhanced STAT3 activation (ratio pSTAT3/STAT3). (b) Western blot analysis and
relevant quantiﬁcation: 5mM LC improved SOD2 protein content in H9c2 cells after 48 and 72 h of treatment with respect to control
cells. Data are expressed as fold changes (FC) of mean± SD. Signiﬁcance: ∗p ≤ 0 05 vs. CONTR; ∗∗p ≤ 0 01 vs. CONTR; §§p ≤ 0 01 vs. LC
0.5mM.
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4. Discussion
In the present study, we demonstrated that LC supplementa-
tion signiﬁcantly decreases ROS production in cardiomyo-
cytes during hyperglycemia (Figure 2). ROS generation
induced by high glucose causes apoptosis of cardiac cells
and important decrease in growth factor secretion [15, 16,
52–55]. In the heart microenvironment, the oxidative stress
induced by hyperglycemia can lead to stem cell senescence
which is characterized by the production and secretion of
FC
72 h
0.0
0.5
1.0
1.5
2.0 I.F. pCaMKII 훼
72 h
0.0
0.5
1.0
1.5
2.0
FC
CONTR CONTR
LC 0.5 mM LC 0.5 mM
LC 5 mM LC 5 mM
pCamKII 훼 72 h CamKII 72 h
I.F. CaMKII 
(a)
72 h
FC
pCaMKII 훼
0.0
0.5
1.0
1.5
⁎
⁎
72 h
pCaMKII 훼
GAPDH
LC 0.5 mM
LC 5 mM
CONTR
LC 0.5 mM LC 5 mMCONTR
(b)
Figure 4: LC downregulation of CaMKII pathway. (a) LC treatments decreased CaMKII-positive cell number and its α phosphorylated form
after 72 h of stimuli: this eﬀect was more marked for the 5mM LC dose. The quantiﬁed signal was normalized for the total nuclei number. (b)
RepresentativeWestern blot and relevant quantiﬁcation: LC stimuli for 72 h promote CaMKII α isoform activation. Data are expressed as fold
changes (FC) of mean± SD. Signiﬁcance: ∗p ≤ 0 05 vs. CONTR.
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soluble factor SASP (senescence-associated secretory pheno-
type). Those factors, responsible for the onset of chronic
inﬂammation and oxidative stress, are considered the patho-
physiological link between aging and diabetes in cardiovas-
cular diseases [56].
The association hyperglycemia/ROS/cellular senescence
represents a major cause of ineﬃciency of regenerative
medicine [9, 10, 56, 57]. Further, clinical trials established
that an altered glycemic control is equal to therapeutic
failure [13, 14]. Our data point out that LC could counter-
act oxidative stress in the hyperglycemic condition. Those
observations are consistent with several previous works that
reported that LC stimuli decrease ROS generation in the
skeletal muscle, bone and cardiac cells grown under nor-
moglycemic condition [26, 27, 58, 59]. Furthermore, as
shown in Figure 6, both doses of LC did not modify the
H9c2 growth rate and did not induce cellular damages.
Studying the mechanism by which LC may modulate
ROS formation, we observed an increase in the serine 727
(Ser727) phosphorylation of STAT3, after 48 and 72 hours
of treatment (Figure 3(a)). Recent evidence stresses the criti-
cal role of STAT3 in modulating mitochondrial respiratory
chain function and ROS production [39, 40]. Serine 727
(Ser727) phosphorylation has a primary part in STAT3
inﬂuence on mitochondria: its decrement is associated with
the development of cardiac hypertrophy and dilated cardio-
myopathy [60]. Moreover, several data showed that STAT3
conserves complex I activity in ischemic condition enhancing
cell viability and plays an important role in heart protection
from chronic stress induced by hyperglycemia [61]. STAT3
activation promotes the expression of SOD2, the principal
enzyme eﬀective in reducing mitochondrial oxidative species
[41, 62]. LC treatment signiﬁcantly increased SOD2 expres-
sion in in vitro cardiomyocytes, conﬁrming LC capability to
counteract oxidative stress in the hyperglycemic condition
(Figure 3(b)).
Interestingly, a number of studies have indicated that
CaMKII enhances mitochondrial dysfunction, ROS forma-
tion, and apoptosis [63], eventually causing cardiomyocyte
death both following hyperglycemia [64, 65] and oxidative
stress conditions [43, 45, 66].
Hyperglycemic cardiac cells are characterized by a
vicious circle between ROS/mitochondrial dysfunction/
CaMKII that triggers cellular damages and apoptosis phe-
nomena [42–44]. Taking into consideration that literature
evidence, we investigated LC action on CaMKII protein con-
tent. As reported in Figure 4, LC treatments reduce CaMKII
activation. Remarkably, recent experiments hypothesized
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Figure 5: LC action on AMPK protein expression. Immunoﬂuorescence assay and relevant quantiﬁcation showed an increase in the number
of AMPK-positive cells in LC condition at 48 and 72 h. The quantiﬁed signal was normalized for the total nuclei number. Data are expressed
as fold changes (FC) of mean± SD. Signiﬁcance: ∗∗∗p ≤ 0 001 vs. CONTR; §§§p ≤ 0 001 vs. LC 5mM.
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that CaMKII activation is related to Ca2+ movement from the
endoplasmic reticulum to mitochondria.
Recently, LC was shown to promote Ca2+ availability
which is needed for proliferation and diﬀerentiation of
human osteoblast-like cells, via a depolarization of L-type
calcium channels [59]. Despite the Ca2+ supply via the
L-type channels being essential to ensure appropriate cardiac
cell contraction, an excessive Ca2+ inﬂux increases mito-
chondrial ROS production in cardiomyocytes under oxida-
tive stress. Various authors suggested that cardiac damage,
induced by CaMKII activation, is caused by an increase in
L-type Ca2+ current [67].
LC capability of modulating CaMKII in cardiac cells
could make LC a molecule appropriate for impeding the
cross-talk between L-type Ca2+ channels and ROS produc-
tion and restoring normal mitochondrial function in cardiac
cells. Further investigations are necessary to unravel LC
action on cardiac calcium channels.
AMPK represents a strategic target in cardiovascular
alterations associated with DM. It is well known that impair-
ment of AMPK activation characterizes hyperglycemic car-
diomyocytes. In particular, during hypoxia/reoxygenation
(H/R) injury in diabetic patients, AMPK deﬁciency is asso-
ciated with an increase in ROS production and apoptosis
[46, 47]. As shown in Figure 5, LC stimuli enhanced AMPK
protein synthesis, suggesting that LC not only could amelio-
rate the oxidative microenvironment but also could improve
metabolic functions of cardiac cells. With this in mind,
future studies could investigate LC’s possible action on the
protein kinase C (PKC) signaling pathway, implicated in
diabetic damage. As known, in hyperglycemic condition,
the decrease in AMPK activity is associated with an increase
of diacylglycerol (DAG) production that activates PKC and
NADPH-oxidase causing an abnormal production of ROS
[68, 69]. Then, LC ability to stimulate AMPK activation
and to regulate the production of acyl-CoA could counter-
act hyperinsulinemia-correlated oxidative stress.
Whereas the higher risk of developing atrial ﬁbrillation
(AF) in diabetic subjects compared to healthy ones is asso-
ciated with mitochondrial ROS overproduction, ATP deple-
tion, and abnormal calcium homeostasis [70, 71], the key
modulator role shown by LC suggests the potential use of this
micronutrient as adjuvant therapy in diﬀerent cardiac
pathologies associated with DM.
In conclusion, LC described eﬀects could be useful in
association with other cardioactive drugs. Ranolazine is an
antianginal drug with hypoglycemic action used in AF treat-
ment, which was shown to enhance skeletal muscle diﬀeren-
tiation [35]. In cardiac regenerative medicine, antioxidative
LC action, in association with ranolazine, might lead to the
improvement of the hyperglycemic-oxidative microenviron-
ment, prevention of apoptosis, and preservation of cell via-
bility. Equally interesting could be the synergistic eﬀect of
LC with allopurinol [72] or the α-lipoic acid antioxidant
[73] in the prevention and treatment of AF. Remarkable
therapeutic perspectives could arise from the association of
LC with new hypoglycemic drugs, such as incretins, whose
eﬀects on the hyperglycemia control, inﬂammation, and
atherosclerotic plaque progression have recently been dem-
onstrated [74, 75].
Taken together, our results argue that the use of LC as a
coadjuvant in therapeutic treatments is very promising,
although extensive studies focused on the determination of
the eﬀective LC dose and route of administration in humans
should be undertaken. Anyway, LC doses used in our study
(0.5–5mM) are compatible with ranges used in humans
receiving LC therapy [76, 77].
5. Conclusion
The results of this work (Table 1) provide, for the ﬁrst time,
fundamental in vitro cellular evidence that treatment with
LC could be a potential strategy to improve the cardiac oxida-
tive microenvironment caused by hyperglycemia.
According to the ﬁndings of the present study, demon-
strating the LC ability to decrease production of ROS, acti-
vate STAT3 and AMPK, and downregulate CaMKII, LC
could represent a potential adjuvant therapeutic strategy in
diabetic cardiac regenerative medicine.
This adjuvant therapy might be recommended for dia-
betic patients with high risk of cardiac injury as it exerts a
cardioprotective eﬀect by restoring the microenvironmen-
tal equilibrium by strengthening cardiomyocytes’ defense
mechanisms through the stimulation of endogenous anti-
oxidants (SOD2).
Further, in vitro and in vivo studies on this topic are essen-
tial to improve the knowledge on the eﬀects of LC in cardiac
diseases associated with diabetes and on its potential synergic
action with other antioxidative and hypoglycemic agents.
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